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INREPLY: Whenwe initially proposeda special issueof Journal of
Clinical Oncology devoted to the cost of cancer care to the editorial
board, our objectivewas to informand stimulate discussion regarding
this complex and increasingly critical topic. In planning “Perspectives
on the Cost of Cancer Care,”1 we were struck by the dearth of
empirical research that had been conducted on the economics of
cancer care. Clearly, this situation is improving, as evidenced by
recent publications in JCO2-4 that stimulated the correspondence
by Lopes and Gluck.
In their letter, the authors address the importance of perspective
in cost-effectiveness (CE) analyses, which serves as the basis for inter-
preting and applying these studies. The greatest value of CE analysis is
to inform decisions regarding allocation of resources from a finite
pot.5 A societal perspective takes into account productivity costs asso-
ciated with cancer and its treatment. Inmost of the clinical literature,
this perspective is not considered as (1) the empirical data are often
shaped by social insurance policies within countries, (2) productivity
costs have been found to vary little across treatment arms of a clinical
trial (thus violating a parsimony objective of clinical research data
collection), and (3) an important component of patient benefit,
quality-adjusted survival, is already considered. From a theoretical
perspective, these costs might be most important to consider when
comparing treatments that offer different outcomes in terms of quan-
tity and quality of life.
The CE analyses regarding trastuzumab therapy in breast cancer
highlight several issues regarding the cost of cancer treatment. First,
expensive drugs such as therapeutic antibodies will appear less so in
adjuvant compared with metastatic settings. Furthermore, drugs for
which a method exists to select patients most likely to benefit (eg,
human epidermal growth factor receptor 2 expression) will have an
advantage in the realmof economic analysis, especially if price was set
before the characterization of the subpopulation was made. Finally,
Lopes and Gluck offer several alternatives to address ethical concerns
over disparities in cancer care, including governmental price controls,
market-based approaches, and restructuring of current incentive
structures for innovation. Space does not permit us to review the pros
and consof eachof these proposals; however,we agree that as a society
there is an urgent need to address the disparities in cancer care (and
health care in general) that are likely to become increasingly acute as
health care costs escalate.6Theoncology communityhas anobligation
to be informed and to participate in these discussions such that we
may impact policy in service to our patients.
Neal J. Meropol
Fox Chase Cancer Center, Philadelphia, PA
Kevin A. Schulman
Duke Clinical Research Institute, Center for Clinical and Genetic Economics,
Duke University, Durham, NC
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One Risk Fits All?
TO THE EDITOR: In the April 10, 2007, issue of the Journal of
Clinical Oncology, Chen and Parmigiani present a set of cancer risk
estimates for counseling and management of BRCA1 and BRCA2
mutation carriers.1 Based on 10 very different studies regarding the
inclusionofpatients, the authors calculatedoverall estimates formean
cumulative cancer risks at age 70.Though the authors observed signif-
icant between-study heterogeneity and discussed several possible
sources, they could not explain it.
We have two concerns regarding the presented risk tables.
First, the studied populations included in the meta-analysis are
very heterogeneous indeed, comprising very high-risk research
families (Breast Cancer Linkage Consortium) as well as high-risk
families ascertained through familial cancer clinics and also cases
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with Ashkenazi-based populations. In doing so, the obtained data
will actually be applicable to neither of these groups nor to the
population that attend family cancer clinics and are in need of
tailored risk figures for counseling and management.
Second, ever since the first reports on cancer risks inBRCA1 and
BRCA2 mutation carriers, the penetrance figures show an overall
decreasing trend in subsequent studies. This is partly due to the fact
that initial families that came for counseling were very strongly af-
fected and to the fact that inclusion criteria for genetic testing have
become less strict over the last decade. Indeed, in the manuscript it is
mentioned that the three most recent familial cancer clinic–based
studieson thepenetranceofBRCA1andBRCA2mutationshave lower
risk estimates.2-4 These studies seem to come closest to the current
setting of familial cancer clinic counseling; therefore, we suggest that
the included studies should not only be stratified by ascertainment,
but also by year of publication.
Up-to-date cancer risk tables for BRCA1 and BRCA2 are defi-
nitely needed for counseling andmanagement, butwe suggest thatwe
should further explore and not pool the sources of heterogeneity and
variation in penetrance. By doing so, we can make cancer risk tables
more population-specific with respect to sources of heterogeneity—
such as ascertainment, ethnic background, family history, and possi-
bly genotype—to facilitate tailored risk counseling.
Geertruida H. De Bock, Marian J.E. Mourits, and
Jan C. Oosterwijk
Department of Epidemiology, Department of Gynaecology, Department of
Genetics, University Medical Center Groningen, University of Groningen,
Groningen, The Netherlands
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IN REPLY: We agree with De Bock et al that it is important to
further explore whether and how penetrance may vary across clinical
populations, and that reliable population-specific risk estimates
wouldhave apositive impact oncounselingpractice.Our study1 is not
to belittle the importance of this endeavor, but to provide reasonable
compromises to be used in risk assessment while these questions are
being addressed.
Apossible source of studyheterogeneity raisedbyDeBock et al is
a decreasing temporal trend in the estimated penetrances. In Figure 1
in Chen et al,1 we arranged studies chronologically so readers could
form an opinion about this issue. The earliest study yielded higher
estimates than the remainder in several age strata. Beyond this obser-
vation, however, we find it difficult to detect a clear temporal pattern.
A recent population-based study by Risch et al2 estimated breast
cancer riskofBRCA1mutationcarriersbyage80at 0.90 (95%CI, 0.77
to 0.97). This further questions the association between risk estimates
and year of publication. Similar considerations apply to other sources
of heterogeneity examined by the original article, which suggests that
we are still at a time when a combined estimate is likely to be useful.
Estimates of the risk of breast cancer for BRCA1 by age 70 range
from 0.36 to 0.71. What should a counselor do in the face of this
variation? Select one of the estimates according to study characteris-
tics, consider all studies, and present a range or risks, or rely on a
compromise? Our software in BayesMendel supports all three op-
tions.3 Selecting one of the estimates may open the door to improved
tailoring, butmay alsobeprone to errors andarbitrariness. Presenting
all estimates has the advantage of being thorough about variation, but
the challenge of communicating this variation and properly incorpo-
rating it into decision making can be daunting. This leaves a broad
range of situations where one size, although it may not fit all, can be
currently practical to many.
Giovanni Parmigiani
Departments of Oncology, Biostatistics, and Pathology, Johns Hopkins
University, Baltimore, MD
Sining Chen
Departments of Environmental Health Sciences and Biostatistics,
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
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